Success Stories: A Research Investigator in Medicinal Chemistry from China Gets EB1-A Approval in a Little Over a Month, Thanks to Premium Processing
Client’s Testimonial:
“Thank you for your great work on my case.”
On May 11th, 2022, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Investigator in the Field of Medicinal Chemistry (Approval Notice).
General Field: Medicinal Chemistry
Position at the Time of Case Filing: Research Investigator
Country of Origin: China
State of Residence at the Time of Filing: Michigan
Approval Notice Date: May 11th, 2022
Processing Time: 1 months, 3 days (Premium Processing Requested)
Case Summary:
The clients who come to us are from various walks of life with varied experiences. This means that our experts have to personalize every petition as per the requirements of the case. This has become one of our hallmarks over a period of time and has helped us win thousands of case approvals. In April of 2022, a client came to us armed with a Ph.D. in medicinal chemistry. He was working as a research investigator in the field at the time.
He was known to be one of the few leading cancer-targeting experts in medicinal chemistry, and he has over time, achieved a consistent and notable record of success and influence in this area of study. Furthermore, his work has resulted in no fewer than 7 commercialized patents that are currently in use by a cancer pharmaceutical corporation.
He has spent years investigating issues related to the development of cancer-targeting pharmaceutical compounds and is regarded as an authority in the field. The field has recognized his authority by inviting him to review and evaluate the work of his peers no fewer than 37 times.
His work has resulted in 10 peer-reviewed scientific articles. Moreover, these papers have been published in some of the most discerning, high-impact journals in his field. Not only this, but his discoveries have also gone on to influence his peers. That is, his publications have been cited by researchers in at least 33 countries according to Google Scholar. At the same time, due to its great applicability in the field, his research in medicinal chemistry has been cited 483 times in other peer-reviewed journal articles. In fact, he is one of the top 1% of most highly cited authors publishing on topics in Medicine & Chemistry over the past 8 years according to Microsoft Academic. This is why experts in the field freely corroborate the value of his work in the following words: “It is clear that his work is of high consequence not just for other researchers, but for the wider world of commercial and industrial utilization. [The client] has proven himself to be a crucial contributor to matters of national health, and his work is, therefore, a necessary good for the country.”
“[Client’s] research led to a discovery of a new treatment method that was significantly more potent than current drugs used to treat this form of cancer. For this reason, his work is moving the field of medicinal chemistry forward by providing solutions to treat problems that have previously been challenging or impossible to overcome. [The client] is thus a key asset to the United States and the welfare of its citizens.”
“With the immense improvements [client] has made in this area of cancer research, his work is invaluable to the health care and the overall economy of the United States of America.”
All of this evidence was thus fully supported and corroborated by letters from internationally recognized experts in the field who have used the client’s work in their own research endeavors and attest to its influence and major significance. The totality of this evidence showed that he is one of that small percentage who has risen to the very top of his field and has sustained both national and international acclaim. Thus we are proud of having been a part of his EB1-A approval journey as well as his NIW and I-485 petition process.